{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:16:33Z","timestamp":1794680193657,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","award":["Muscular Dystrophy Canada"],"award-info":[{"award-number":["Muscular Dystrophy Canada"]}],"id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by the loss of the <jats:italic>SMN1<\/jats:italic> gene, with an estimated birth prevalence of about 1 in 10,000. Early intervention with disease-modifying therapies (DMTs) significantly improves outcomes. This study evaluates the economic implications and health benefits of newborn screening (NBS) for SMA in Canada from the societal perspective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A decision analytic model was developed, which combined a decision tree for the screening algorithm and a Markov model for long-term health outcomes. The Markov model included health states based on WHO motor milestones. The population cohort of 357,903 live newborns reflects the 2022\u20132023 births in Canada. Screening is performed on dried blood spot testing which evaluates for biallelic deletions in <jats:italic>SMN1<\/jats:italic>. Cost inputs encompassed treatment and health state costs, while utility values reflected quality of life in each health state.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>NBS for SMA is expected to identify 37.1 (95% CI: 15.0, 70.7) newborns annually in Canada. Our analysis over a lifetime horizon and a discount rate of 1.5% shows NBS and early treatment has an incremental cost of -$146,187,000 (95% CI: -249,773,777 to \u2212\u200917,890,034) and incremental benefit of 872 (95% CI: -193, 2329) quality-adjusted life years (QALYs) compared to no NBS and late treatment. This resulted in a mean ICER value of -$173,572\/QALY.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The decision analytic model indicated that overall NBS is cost-saving and more effective than no NBS and late treatment in the Canadian health system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03927-6","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T12:43:24Z","timestamp":1755089004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A cost-utility analysis of newborn screening for spinal muscular atrophy in Canada"],"prefix":"10.1186","volume":"20","author":[{"given":"Alex","family":"Pace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weston","family":"Roda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrina","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Oskoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranesh","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Round","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"3927_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11\u201325.","journal-title":"Appl Clin Genet"},{"issue":"4","key":"3927_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"2","key":"3927_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/cjn.2023.34","volume":"51","author":"E Groulx-Boivin","year":"2024","unstructured":"Groulx-Boivin E, Osman H, Chakraborty P, Lintern S, Oskoui M, Selby K, et al. Variability in newborn screening across canada: spinal muscular atrophy and beyond. Can J Neurol Sci. 2024;51(2):203\u20139.","journal-title":"Can J Neurol Sci"},{"key":"3927_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013 a literature review. Orphanet J Rare Dis. 2017;12:124.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3927_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijns9030042","volume":"9","author":"F Niri","year":"2023","unstructured":"Niri F, Nicholls J, Baptista Wyatt K, Walker C, Price T, Kelln R, et al. Alberta spinal muscular atrophy newborn Screening\u2014Results from year 1 pilot project. Int J Neonatal Screen. 2023;9(3):42.","journal-title":"Int J Neonatal Screen"},{"issue":"6","key":"3927_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1017\/cjn.2021.231","volume":"49","author":"KD Kernohan","year":"2022","unstructured":"Kernohan KD, McMillan HJ, Yeh E, Lacaria M, Kowalski M, Campbell C, et al. Ontario newborn screening for spinal muscular atrophy: the first year. Can J Neurol Sci. 2022;49(6):821\u20133.","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"3927_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"3927_CR8","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137.","journal-title":"Nat Med"},{"key":"3927_CR9","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.nmd.2022.07.183","volume":"32","author":"R Finkel","year":"2022","unstructured":"Finkel R, Farrar M, Vlodavets D, Zanoteli E, Al-Muhaizea M, Nelson L, et al. FP.24 RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Neuromuscul Disord. 2022;32:S85\u20136.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3927_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular Atrophy \u2013 new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis"},{"key":"3927_CR11","unstructured":"Newborn Screening. \u2013 Muscular Dystrophy Canada [Internet]. [cited 2024 Jun 17]. Available from: https:\/\/muscle.ca\/services-support\/newborn-screening\/"},{"issue":"S450","key":"3927_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"95","author":"M De Onis","year":"2006","unstructured":"WHO MULTICENTRE GROWTH REFERENCE STUDY GROUP, De Onis M, WHO Motor Development Study. Windows of achievement for six gross motor development milestones. Acta Paediatr. 2006;95(S450):86\u201395.","journal-title":"Acta Paediatr"},{"key":"3927_CR13","doi-asserted-by":"publisher","unstructured":"Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England. Neurol Ther [Internet]. 2023 May 24 [cited 2023 Jun 16]; Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s40120-023-00489-2","DOI":"10.1007\/s40120-023-00489-2"},{"issue":"10","key":"3927_CR14","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-Effectiveness of newborn screening for spinal muscular atrophy in the Netherlands. Value Health. 2022;25(10):1696\u2013704.","journal-title":"Value Health"},{"issue":"21","key":"3927_CR15","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy. Neurology. 2019;92(21):e2492\u2013506.","journal-title":"Neurology"},{"issue":"4","key":"3927_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"key":"3927_CR17","unstructured":"Guidelines for the Economic Evaluation of Health Technologies. Canada \u2014 4th Edition | CDA-AMC [Internet]. [cited 2024 Jun 18]. Available from: https:\/\/www-cadth-ca.proxy.bib.uottawa.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition"},{"key":"3927_CR18","unstructured":"Government of Canada SC. Estimates of births, by gender, annual [Internet]. 2018 [cited 2024 Jun 18]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710001601"},{"key":"3927_CR19","unstructured":"Newborn Screening. \u2013 Muscular Dystrophy Canada [Internet]. [cited 2024 Jun 18]. Available from: https:\/\/muscle.ca\/services-support\/newborn-screening\/"},{"issue":"12","key":"3927_CR20","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1373\/clinchem.2018.293712","volume":"64","author":"N Vidal-Folch","year":"2018","unstructured":"Vidal-Folch N, Gavrilov D, Raymond K, Rinaldo P, Tortorelli S, Matern D, et al. Multiplex droplet digital PCR method applicable to newborn screening, carrier status, and assessment of spinal muscular atrophy. Clin Chem. 2018;64(12):1753\u201361.","journal-title":"Clin Chem"},{"key":"3927_CR21","doi-asserted-by":"publisher","unstructured":"Nigro E, Grunebaum E, Kamath B, Licht C, Malcolmson C, Jeewa A et al. Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment. Front Neurol [Internet]. 2023 Sep 12 [cited 2024 May 8];14. Available from: https:\/\/www.frontiersin.org\/journals\/neurology\/articles\/https:\/\/doi.org\/10.3389\/fneur.2023.1230889\/full","DOI":"10.3389\/fneur.2023.1230889\/full"},{"key":"3927_CR22","doi-asserted-by":"publisher","first-page":"101117","DOI":"10.1016\/j.omtm.2023.101117","volume":"31","author":"JW Day","year":"2023","unstructured":"Day JW, Mendell JR, Burghes AHM, Van Olden RW, Adhikary RR, Dilly KW. Adeno-associated virus serotype 9 antibody Seroprevalence for patients in the united States with spinal muscular atrophy. Mol Therapy - Methods Clin Dev. 2023;31:101117.","journal-title":"Mol Therapy - Methods Clin Dev"},{"key":"3927_CR23","unstructured":"Government of Canada SC. Population estimates on July 1, by age and gender [Internet]. 2018 [cited 2024 Jun 19]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000501"},{"key":"3927_CR24","unstructured":"Government of Canada SC. Life expectancy and other elements of the complete life table, three-year estimates, Canada, all provinces except Prince Edward Island [Internet]. 2021 [cited 2024 Jun 19]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011401"},{"issue":"1","key":"3927_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372.","journal-title":"J Neurol Sci"},{"issue":"9","key":"3927_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"6","key":"3927_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"issue":"5","key":"3927_CR28","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rav\u00e0 L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314.","journal-title":"Pediatrics"},{"key":"3927_CR29","unstructured":"Schedule of benefits for Laboratory Services. Laboratory Medicine. 2020."},{"key":"3927_CR30","unstructured":"Abeparvovec O, Novartis Pharmaceuticals Canada Inc. Indication: for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and: \u2022 3 or fewer copies of SMN2 gene; or \u2022 infantile-onset SMA. 2021."},{"key":"3927_CR31","unstructured":"Nusinersen for Adolescents and Adults with Spinal Muscular Atrophy. A Review of Clinical Effectiveness | CDA-AMC [Internet]. [cited 2024 Jun 19]. Available from: https:\/\/www.cadth.ca\/nusinersen-adolescents-and-adults-spinal-muscular-atrophy-review-clinical-effectiveness"},{"key":"3927_CR32","unstructured":"risdiplam | CDA-AMC [Internet]. [cited 2024 Jun 19]. Available from: https:\/\/www.cadth.ca\/risdiplam"},{"issue":"4","key":"3927_CR33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1017\/cjn.2020.229","volume":"48","author":"HJ McMillan","year":"2021","unstructured":"McMillan HJ, Kernohan KD, Yeh E, Amburgey K, Boyd J, Campbell C, et al. Newborn screening for spinal muscular atrophy: Ontario testing and Follow-up recommendations. Can J Neurol Sci. 2021;48(4):504\u201311.","journal-title":"Can J Neurol Sci"},{"issue":"sup1","key":"3927_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13696998.2021.2013676","volume":"24","author":"G Chen","year":"2021","unstructured":"Chen G, Sharif B, Gerber B, Farris MS, Cowling T, Cabalteja C, et al. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in alberta, Canada. J Med Econ. 2021;24(sup1):51\u20139.","journal-title":"J Med Econ"},{"issue":"4","key":"3927_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JND-200610","volume":"8","author":"HJ McMillan","year":"2021","unstructured":"McMillan HJ, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553\u201368.","journal-title":"J Neuromuscul Dis"},{"key":"3927_CR36","unstructured":"Hospital spending | CIHI [Internet]. [cited 2024 Jun 19]. Available from: https:\/\/www.cihi.ca\/en\/hospital-spending"},{"key":"3927_CR37","doi-asserted-by":"publisher","unstructured":"Sejersen T, Graham S, Ekstr\u00f6m AB, Kroksmark AK, Kwiatkowska M, Ganz ML et al. Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden. Eur J Health Econ [Internet]. 2024 Apr 20 [cited 2024 Apr 30]; Available from: https:\/\/doi.org\/10.1007\/s10198-024-01678-y","DOI":"10.1007\/s10198-024-01678-y"},{"key":"3927_CR38","unstructured":"Cost of a Standard. Hospital Stay \u00b7 CIHI [Internet]. [cited 2024 Apr 30]. Available from: https:\/\/yourhealthsystem.cihi.ca\/hsp\/inbrief#!\/indicators\/015\/cost-of-a-standard-hospital-stay\/;mapC1;mapLevel2;\/"},{"key":"3927_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11:58.","journal-title":"Orphanet J Rare Dis"},{"key":"3927_CR40","doi-asserted-by":"crossref","unstructured":"Nonoyama ML, McKim DA, Road J, Guerriere D, Coyte PC, Wasilewski M et al. Healthcare utilisation and costs of home mechanical ventilation. Thorax. 2018;thoraxjnl-2017-211138.","DOI":"10.1183\/13993003.congress-2019.PA1043"},{"key":"3927_CR41","unstructured":"Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular."},{"key":"3927_CR42","first-page":"29","volume":"34","author":"M Molina","year":"2023","unstructured":"Molina M, Humphries B, Guertin J, Feeny D, Tarride JE. Health utilities index mark 3 scores for children and youth: population norms for Canada based on cycles 5 (2016 and 2017) and 6 (2018 and 2019) of the Canadian health measures survey. Health Rep. 2023;34:29\u201339.","journal-title":"Health Rep"},{"key":"3927_CR43","unstructured":"Government of Canada SC. Health Utilities Index Mark 3 scores for children and youth: Population norms for Canada based on cycles 5 (2016 and 2017) and 6 (2018 and 2019) of the Canadian Health Measures Survey [Internet]. 2023 [cited 2024 Jun 19]. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-003-x\/2023002\/article\/00003-eng.htm"},{"key":"3927_CR44","doi-asserted-by":"publisher","unstructured":"Adalsteinsson E, Toumi M. Benefits of probabilistic sensitivity analysis \u2013 a review of NICE decisions. J Mark Access Health Policy. 2013;1. https:\/\/doi.org\/10.3402\/jmahp.v1i0.21240.","DOI":"10.3402\/jmahp.v1i0.21240"},{"key":"3927_CR45","first-page":"111","volume":"5","author":"S Portet","year":"2020","unstructured":"Portet S. A primer on model selection using the Akaike information criterion. Infect Dis Model. 2020;5:111\u201328.","journal-title":"Infect Dis Model"},{"issue":"1","key":"3927_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2140\/camcos.2010.5.65","volume":"5","author":"J Goodman","year":"2010","unstructured":"Goodman J, Weare J. Ensemble samplers with affine invariance. Commun Appl Math Comput Sci. 2010;5(1):65\u201380.","journal-title":"Commun Appl Math Comput Sci"},{"key":"3927_CR47","doi-asserted-by":"crossref","unstructured":"Decision Modelling for Health Economic Evaluation, Briggs A, Sculpher M, Claxton K.| International Journal of Epidemiology | Oxford Academic [Internet]. [cited 2024 Aug 22]. Available from: https:\/\/academic.oup.com\/ije\/article\/36\/2\/476\/725641","DOI":"10.1093\/ije\/dym062"},{"issue":"1","key":"3927_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","volume":"22","author":"M Sittimart","year":"2024","unstructured":"Sittimart M, Rattanavipapong W, Mirelman AJ, Hung TM, Dabak S, Downey LE, et al. An overview of the perspectives used in health economic evaluations. Cost Eff Resource Allocation. 2024;22(1):41.","journal-title":"Cost Eff Resource Allocation"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03927-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:47:29Z","timestamp":1757422049000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3927"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03927-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HM has been a consultant and received honararia from Novartis Gene Therapies Inc, Hoffman La-Roche Ltd and Pfizer. He has participated in clinical trials with Roche, PTC Therapeutics, Biogen, DYNE, PepGen, ReveraGen, Catabasis, Novartis, and Sarepta. MO has received research support from Roche Genetech, Novartis, Santhera, Muscular Dystrophy Canada, Canadian Institutes of Health Research. PC has received research support from Biogen, Biomarin, Takeda, Cambrooke, Vitaflo, Nutricia, NFDC, CIHR and CF foundation. He has also served on advisory boards for Sanofi, Ultragenyx, Waters and Horizon. JR and his employer (The Institute of Health Economics) received no additional funding directly related to this work. AP has no disclosures to report. CP has no disclosures to report. WR has no disclosures to report. AM has no disclosures to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"428"}}